Grant Number:	1R21CA127768-01A1 Interpret this number
Primary Investigator:	Lilja, Hans
Organization:	Sloan-Kettering Inst Can Research
Project Title:	Long-Term Prediction of Prostate Cancer Death From Kallikreins Measured in Blood
Fiscal Year:	2008

DESCRIPTION (provided by applicant): We will determine whether kallikrein forms (prostate-specific antigen [PSA] and kallikrein 2 [hK2]) measured in men aged 44 - 50 predict subsequent metastases or death from prostate cancer. No previous study have evaluated whether a biomarker analyzed in a healthy volunteer population predicts metastases or cancer-specific death many years (typically 15-35 years) later. Low incidence of PSA testing in Sweden during enrollment (1974-1986) and long-term follow-up are prerequisites for our unique "natural experiment". We do not ask "can we detect prostate cancer?" but "can we predict prostate cancers with important impact on quality of life or reduced life expectancy?" We wish to predict risk of metastases or death from prostate cancer to risk-stratify screening and chemoprevention strategies, which must be made before these efforts start; i.e. in age 44- 50. We will first determine whether highly optimized measures of PSA and hK2 in blood collected at age =50 predict later development of metastases or death from prostate cancer; go on to determine whether measures in a 2nd sample (collected 6 years later) enhances these predictions. We will build statistical models to predict an individual man's probability of metastases or death from prostate cancer using single, or repeated measures at ages 44 - 55. If these models have sufficient accuracy in the R21 phase, we will go on in the R33 phase to determine their accuracy on an independent cohort of 40,000 men. Many common problems are avoided. These include over-diagnosis: we know that PSA detects prostate cancer at early, curable stages with high sensitivity (but poor specificity), however, many PSA-detected cancers would never cause morbidity or mortality to the patient before he dies of other causes. Studies are also affected by selection bias: men with family history or other risk factors are more likely to attend screening; and lead-time bias, where apparent survival advantage only relates to early time of diagnosis. Regarding the key issue of over-diagnosis, our study endpoint is death, or metastatic disease. There will be little if any selection bias due to low incidence of PSA screening in our study cohorts. Due to the retrospective nature of the study, the participants are never influenced by any PSA-data, and we will not be subject to lead- time bias as we will not compare survival between screened vs. unscreened cohorts. Using blood samples taken in Sweden in the mid-1970s - 1980s, we were able to show that a single blood test at age 44 - 50 can predict prostate cancer up to 25 years later. As many more men are diagnosed with prostate cancer than who die from the disease, the current proposal is to extend our work to determine if we can predict prostate cancer death. If so, a single blood test could be used to identify men at highest risk from prostate cancer and particular efforts could then be made for intensive screening and chemoprevention for these individuals.




Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
Authors: Preston M.A. , Gerke T. , Carlsson S.V. , Signorello L. , Sjoberg D.D. , Markt S.C. , Kibel A.S. , Trinh Q.D. , Steinwandel M. , Blot W. , et al. .
Source: European Urology, 2019 03; 75(3), p. 399-407.
EPub date: 2018-09-17 00:00:00.0.
PMID: 30237027
Related Citations

Long-term prediction of prostate cancer diagnosis and death using PSA and obesity related anthropometrics at early middle age: data from the malmö preventive project.
Authors: Assel M.J. , Gerdtsson A. , Thorek D.L.J. , Carlsson S.V. , Malm J. , Scardino P.T. , Vickers A. , Lilja H. , Ulmert D. .
Source: Oncotarget, 2018-01-19 00:00:00.0; 9(5), p. 5778-5785.
EPub date: 2017-12-05 00:00:00.0.
PMID: 29464033
Related Citations

Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.
Authors: Carlsson S. , Assel M. , Ulmert D. , Gerdtsson A. , Hugosson J. , Vickers A. , Lilja H. .
Source: European Urology, 2017 Jan; 71(1), p. 46-52.
PMID: 27084245
Related Citations

Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis.
Authors: Thorek D.L. , Watson P.A. , Lee S.G. , Ku A.T. , Bournazos S. , Braun K. , Kim K. , Sjöström K. , Doran M.G. , Lamminmäki U. , et al. .
Source: Science Translational Medicine, 2016-11-30 00:00:00.0; 8(367), p. 367ra167.
PMID: 27903863
Related Citations

Baseline Prostate-specific Antigen Levels In Midlife Predict Lethal Prostate Cancer
Authors: Preston M.A. , Batista J.L. , Wilson K.M. , Carlsson S.V. , Gerke T. , Sjoberg D.D. , Dahl D.M. , Sesso H.D. , Feldman A.S. , Gann P.H. , et al. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2016-08-10 00:00:00.0; 34(23), p. 2705-11.
PMID: 27298404
Related Citations

The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening.
Authors: Vickers A.J. , Eastham J.A. , Scardino P.T. , Lilja H. .
Source: Urology, 2016 05; 91, p. 12-8.
PMID: 26850815
Related Citations

Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death.
Authors: Gerdtsson A. , Poon J.B. , Thorek D.L. , Mucci L.A. , Evans M.J. , Scardino P. , Abrahamsson P.A. , Nilsson P. , Manjer J. , Bjartell A. , et al. .
Source: European Urology, 2015 Dec; 68(6), p. 1076-82.
PMID: 25794458
Related Citations

Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.
Authors: Stattin P. , Vickers A.J. , Sjoberg D.D. , Johansson R. , Granfors T. , Johansson M. , Pettersson K. , Scardino P.T. , Hallmans G. , Lilja H. .
Source: European Urology, 2015 Aug; 68(2), p. 207-13.
PMID: 25682340
Related Citations

Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.
Authors: Nordström T. , Vickers A. , Assel M. , Lilja H. , Grönberg H. , Eklund M. .
Source: European Urology, 2015 Jul; 68(1), p. 139-46.
PMID: 25151013
Related Citations

Concurrent isolation of lymphocytes and granulocytes using prefocused free flow acoustophoresis.
Authors: Grenvall C. , Magnusson C. , Lilja H. , Laurell T. .
Source: Analytical Chemistry, 2015-06-02 00:00:00.0; 87(11), p. 5596-604.
EPub date: 2015-06-02 00:00:00.0.
PMID: 25909882
Related Citations

Serum markers in prostate cancer detection.
Authors: Bratt O. , Lilja H. .
Source: Current Opinion In Urology, 2015 Jan; 25(1), p. 59-64.
PMID: 25393274
Related Citations

The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Authors: Vedder M.M. , de Bekker-Grob E.W. , Lilja H.G. , Vickers A.J. , van Leenders G.J. , Steyerberg E.W. , Roobol M.J. .
Source: European Urology, 2014 Dec; 66(6), p. 1109-15.
PMID: 25168616
Related Citations

Identification of plasma protein profiles associated with risk groups of prostate cancer patients.
Authors: Nordström M. , Wingren C. , Rose C. , Bjartell A. , Becker C. , Lilja H. , Borrebaeck C.A. .
Source: Proteomics. Clinical Applications, 2014 Dec; 8(11-12), p. 951-62.
PMID: 25196118
Related Citations

Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
Authors: Ankerst D.P. , Boeck A. , Freedland S.J. , Jones J.S. , Cronin A.M. , Roobol M.J. , Hugosson J. , Kattan M.W. , Klein E.A. , Hamdy F. , et al. .
Source: World Journal Of Urology, 2014 Feb; 32(1), p. 185-91.
PMID: 22527674
Related Citations

Cancer-associated changes in the expression of TMPRSS2-ERG, PCA3, and SPINK1 in histologically benign tissue from cancerous vs noncancerous prostatectomy specimens.
Authors: Väänänen R.M. , Lilja H. , Kauko L. , Helo P. , Kekki H. , Cronin A.M. , Vickers A.J. , Nurmi M. , Alanen K. , Bjartell A. , et al. .
Source: Urology, 2014 Feb; 83(2), p. 511.e1-7.
PMID: 24468524
Related Citations

Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.
Authors: Carlsson S. , Maschino A. , Schröder F. , Bangma C. , Steyerberg E.W. , van der Kwast T. , van Leenders G. , Vickers A. , Lilja H. , Roobol M.J. .
Source: European Urology, 2013 Nov; 64(5), p. 693-9.
PMID: 23683475
Related Citations

Identification of a novel proteoform of prostate specific antigen (SNP-L132I) in clinical samples by multiple reaction monitoring.
Authors: Végvári A. , Sjödin K. , Rezeli M. , Malm J. , Lilja H. , Laurell T. , Marko-Varga G. .
Source: Molecular & Cellular Proteomics : Mcp, 2013 Oct; 12(10), p. 2761-73.
PMID: 23842001
Related Citations

Improved porous silicon microarray based prostate specific antigen immunoassay by optimized surface density of the capture antibody.
Authors: Lee S. , Kim S. , Malm J. , Jeong O.C. , Lilja H. , Laurell T. .
Source: Analytica Chimica Acta, 2013-09-24 00:00:00.0; 796, p. 108-14.
EPub date: 2013-09-24 00:00:00.0.
PMID: 24016590
Related Citations

Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years.
Authors: Christensson A. , Savage C. , Sjoberg D.D. , Cronin A.M. , O'Brien M.F. , Lowrance W. , Nilsson P.M. , Vickers A.J. , Russo P. , Lilja H. .
Source: International Journal Of Cancer, 2013-09-15 00:00:00.0; 133(6), p. 1452-8.
EPub date: 2013-09-15 00:00:00.0.
PMID: 23463659
Related Citations

Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?
Authors: Carlsson S.V. , Peltola M.T. , Sjoberg D. , Schröder F.H. , Hugosson J. , Pettersson K. , Scardino P.T. , Vickers A.J. , Lilja H. , Roobol M.J. .
Source: Bju International, 2013 Sep; 112(5), p. 602-9.
PMID: 23448270
Related Citations

Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort.
Authors: Larsen S.B. , Brasso K. , Iversen P. , Christensen J. , Christiansen M. , Carlsson S. , Lilja H. , Friis S. , Tjønneland A. , Dalton S.O. .
Source: European Journal Of Cancer (oxford, England : 1990), 2013 Sep; 49(14), p. 3041-8.
PMID: 23684783
Related Citations

Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles.
Authors: Thorek D.L. , Evans M.J. , Carlsson S.V. , Ulmert D. , Lilja H. .
Source: Thrombosis And Haemostasis, 2013 Sep; 110(3), p. 484-92.
PMID: 23903407
Related Citations

Integrated acoustic immunoaffinity-capture (IAI) platform for detection of PSA from whole blood samples.
Authors: Tajudin A.A. , Petersson K. , Lenshof A. , Swärd-Nilsson A.M. , Aberg L. , Marko-Varga G. , Malm J. , Lilja H. , Laurell T. .
Source: Lab On A Chip, 2013-05-07 00:00:00.0; 13(9), p. 1790-6.
PMID: 23515524
Related Citations

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.
Authors: Vickers A.J. , Ulmert D. , Sjoberg D.D. , Bennette C.J. , Björk T. , Gerdtsson A. , Manjer J. , Nilsson P.M. , Dahlin A. , Bjartell A. , et al. .
Source: Bmj (clinical Research Ed.), 2013-04-15 00:00:00.0; 346, p. f2023.
EPub date: 2013-04-15 00:00:00.0.
PMID: 23596126
Related Citations

Levels of beta-microseminoprotein in blood and risk of prostate cancer in multiple populations.
Authors: Haiman C.A. , Stram D.O. , Vickers A.J. , Wilkens L.R. , Braun K. , Valtonen-André C. , Peltola M. , Pettersson K. , Waters K.M. , Marchand L.L. , et al. .
Source: Journal Of The National Cancer Institute, 2013-02-06 00:00:00.0; 105(3), p. 237-43.
EPub date: 2013-02-06 00:00:00.0.
PMID: 23213189
Related Citations

Chromosome 19 annotations with disease speciation: a first report from the Global Research Consortium.
Authors: Nilsson C.L. , Berven F. , Selheim F. , Liu H. , Moskal J.R. , Kroes R.A. , Sulman E.P. , Conrad C.A. , Lang F.F. , Andrén P.E. , et al. .
Source: Journal Of Proteome Research, 2013-01-04 00:00:00.0; 12(1), p. 135-50.
EPub date: 2013-01-04 00:00:00.0.
PMID: 23249167
Related Citations

Genome-wide association study identifies loci at ATF7IP and KLK2 associated with percentage of circulating free PSA.
Authors: Jin G. , Zheng S.L. , Lilja H. , Kim S.T. , Tao S. , Gao Z. , Young T. , Wiklund F. , Feng J. , Isaacs W.B. , et al. .
Source: Neoplasia (new York, N.y.), 2013 Jan; 15(1), p. 95-101.
PMID: 23359319
Related Citations

Microchannel acoustophoresis does not impact survival or function of microglia, leukocytes or tumor cells.
Authors: Burguillos M.A. , Magnusson C. , Nordin M. , Lenshof A. , Augustsson P. , Hansson M.J. , Elmér E. , Lilja H. , Brundin P. , Laurell T. , et al. .
Source: Plos One, 2013; 8(5), p. e64233.
PMID: 23724038
Related Citations

Copy number variants in the kallikrein gene cluster.
Authors: Lindahl P. , Säll T. , Bjartell A. , Johansson A.M. , Lilja H. , Halldén C. .
Source: Plos One, 2013; 8(7), p. e69097.
PMID: 23894413
Related Citations

Porous silicon antibody microarrays for quantitative analysis: measurement of free and total PSA in clinical plasma samples.
Authors: Järås K. , Adler B. , Tojo A. , Malm J. , Marko-Varga G. , Lilja H. , Laurell T. .
Source: Clinica Chimica Acta; International Journal Of Clinical Chemistry, 2012-12-24 00:00:00.0; 414, p. 76-84.
EPub date: 2012-12-24 00:00:00.0.
PMID: 22921878
Related Citations

Risk of cancer-specific mortality following recurrence after radical nephroureterectomy.
Authors: Rink M. , Sjoberg D. , Comploj E. , Margulis V. , Xylinas E. , Lee R.K. , Hansen J. , Cha E.K. , Raman J.D. , Remzi M. , et al. .
Source: Annals Of Surgical Oncology, 2012 Dec; 19(13), p. 4337-44.
PMID: 22805867
Related Citations

Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses.
Authors: Ulmert D. , Vickers A.J. , Scher H.I. , Becker C. , Iversen P. , Frankel D. , Jensen J.K. , Olesen T.K. , Lilja H. .
Source: Clinical Chemistry And Laboratory Medicine, 2012 Nov; 50(11), p. 1993-8.
PMID: 22718641
Related Citations

Microfluidic, label-free enrichment of prostate cancer cells in blood based on acoustophoresis.
Authors: Augustsson P. , Magnusson C. , Nordin M. , Lilja H. , Laurell T. .
Source: Analytical Chemistry, 2012-09-18 00:00:00.0; 84(18), p. 7954-62.
EPub date: 2012-09-18 00:00:00.0.
PMID: 22897670
Related Citations

Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.
Authors: Carlsson S. , Vickers A.J. , Roobol M. , Eastham J. , Scardino P. , Lilja H. , Hugosson J. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2012-07-20 00:00:00.0; 30(21), p. 2581-4.
EPub date: 2012-07-20 00:00:00.0.
PMID: 22711853
Related Citations

A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.
Authors: Ulmert D. , Kaboteh R. , Fox J.J. , Savage C. , Evans M.J. , Lilja H. , Abrahamsson P.A. , Björk T. , Gerdtsson A. , Bjartell A. , et al. .
Source: European Urology, 2012 Jul; 62(1), p. 78-84.
PMID: 22306323
Related Citations

Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.
Authors: Evans-Axelsson S. , Ulmert D. , Örbom A. , Peterson P. , Nilsson O. , Wennerberg J. , Strand J. , Wingårdh K. , Olsson T. , Hagman Z. , et al. .
Source: Cancer Biotherapy & Radiopharmaceuticals, 2012 May; 27(4), p. 243-51.
PMID: 22489659
Related Citations

Predicting prostate cancer many years before diagnosis: how and why?
Authors: Vickers A.J. , Lilja H. .
Source: World Journal Of Urology, 2012 Apr; 30(2), p. 131-5.
PMID: 22101902
Related Citations

Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
Authors: Ankerst D.P. , Boeck A. , Freedland S.J. , Thompson I.M. , Cronin A.M. , Roobol M.J. , Hugosson J. , Stephen Jones J. , Kattan M.W. , Klein E.A. , et al. .
Source: World Journal Of Urology, 2012 Apr; 30(2), p. 181-7.
PMID: 22210512
Related Citations

Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.
Authors: Ulmert D. , Evans M.J. , Holland J.P. , Rice S.L. , Wongvipat J. , Pettersson K. , Abrahamsson P.A. , Scardino P.T. , Larson S.M. , Lilja H. , et al. .
Source: Cancer Discovery, 2012 Apr; 2(4), p. 320-7.
PMID: 22576209
Related Citations

Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.
Authors: Klein R.J. , Hallden C. , Gupta A. , Savage C.J. , Dahlin A. , Bjartell A. , Manjer J. , Scardino P.T. , Ulmert D. , Wallström P. , et al. .
Source: European Urology, 2012 Mar; 61(3), p. 471-7.
PMID: 22101116
Related Citations

PSA is dead, long live PSA.
Authors: Vickers A.J. , Lilja H. .
Source: European Urology, 2012 Mar; 61(3), p. 467-8; discussion 469-70.
PMID: 22168949
Related Citations

Molecular microheterogeneity of prostate specific antigen in seminal fluid by mass spectrometry.
Authors: Végvári Á. , Rezeli M. , Sihlbom C. , Häkkinen J. , Carlsohn E. , Malm J. , Lilja H. , Laurell T. , Marko-Varga G. .
Source: Clinical Biochemistry, 2012 Mar; 45(4-5), p. 331-8.
PMID: 22209970
Related Citations

Assessing the incremental value of diagnostic and prognostic markers: a review and illustration.
Authors: Steyerberg E.W. , Pencina M.J. , Lingsma H.F. , Kattan M.W. , Vickers A.J. , Van Calster B. .
Source: European Journal Of Clinical Investigation, 2012 Feb; 42(2), p. 216-28.
PMID: 21726217
Related Citations

Screening for prostate cancer: early detection or overdetection?
Authors: Vickers A.J. , Roobol M.J. , Lilja H. .
Source: Annual Review Of Medicine, 2012; 63, p. 161-70.
PMID: 22053739
Related Citations

Urological cancer: Time for another rethink on prostate cancer screening.
Authors: Vickers A.J. , Lilja H. .
Source: Nature Reviews. Clinical Oncology, 2011-11-29 00:00:00.0; 9(1), p. 7-8.
EPub date: 2011-11-29 00:00:00.0.
PMID: 22124367
Related Citations

Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
Authors: Christensson A. , Bruun L. , Björk T. , Cronin A.M. , Vickers A.J. , Savage C.J. , Lilja H. .
Source: Bju International, 2011 Jun; 107(11), p. 1769-74.
PMID: 20955263
Related Citations

Tumor markers in prostate cancer I: blood-based markers.
Authors: Shariat S.F. , Semjonow A. , Lilja H. , Savage C. , Vickers A.J. , Bjartell A. .
Source: Acta Oncologica (stockholm, Sweden), 2011 Jun; 50 Suppl 1, p. 61-75.
PMID: 21604943
Related Citations

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.
Authors: Lilja H. , Cronin A.M. , Dahlin A. , Manjer J. , Nilsson P.M. , Eastham J.A. , Bjartell A.S. , Scardino P.T. , Ulmert D. , Vickers A.J. .
Source: Cancer, 2011-03-15 00:00:00.0; 117(6), p. 1210-9.
EPub date: 2011-03-15 00:00:00.0.
PMID: 20960520
Related Citations

A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.
Authors: Vickers A.J. , Gupta A. , Savage C.J. , Pettersson K. , Dahlin A. , Bjartell A. , Manjer J. , Scardino P.T. , Ulmert D. , Lilja H. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2011 Feb; 20(2), p. 255-61.
PMID: 21148123
Related Citations

A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France.
Authors: Benchikh A. , Savage C. , Cronin A. , Salama G. , Villers A. , Lilja H. , Vickers A. .
Source: Bmc Cancer, 2010-11-22 00:00:00.0; 10, p. 635.
EPub date: 2010-11-22 00:00:00.0.
PMID: 21092177
Related Citations